HC Wainwright Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)

HC Wainwright reissued their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

Other equities analysts also recently issued research reports about the company. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com started coverage on Moleculin Biotech in a research note on Thursday, March 13th. They set a “sell” rating for the company.

Moleculin Biotech Trading Down 2.8 %

Shares of Moleculin Biotech stock opened at $1.06 on Monday. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $6.23. The firm has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $2.01.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.